Table 3.
Logistic regression analysis of the risk factors of postoperative AE-ILD.
| Variables | ALL (n = 152) | Lobectomy (n = 77) | Sublobar resection (n = 75) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P-value | OR | 95% CI | P-value | OR | 95% CI | P-value | |
| (a) Univariate analysis | |||||||||
| Age, years | 0.975 | 0.911–1.045 | 0.475 | 0.949 | 0.865–1.041 | 0.266 | 1.025 | 0.920–1.143 | 0.652 |
| Sex, male | Not calculated | Not calculated | Not calculated | ||||||
| Smoking history, pack-years | 1.010 | 0.999–1.020 | 0.076 | 1.013 | 0.999–1.026 | 0.058 | 1.003 | 0.984–1.022 | 0.771 |
| VC, % predicted | 0.965 | 0.936–0.994 | 0.020* | 0.948 | 0.895–1.005 | 0.072 | 0.963 | 0.924–1.004 | 0.075 |
| FVC, % predicted | 0.970 | 0.938–1.003 | 0.077 | 0.969 | 0.916–1.025 | 0.267 | 0.965 | 0.922–1.011 | 0.132 |
| FEV1, % predicted | 0.970 | 0.943–1.000 | 0.045* | 0.959 | 0.915–1.005 | 0.083 | 0.976 | 0.937–1.017 | 0.247 |
| FEV1/FVC, % | 1.036 | 0.986–1.089 | 0.163 | 1.046 | 0.974–1.123 | 0.221 | 1.032 | 0.959–1.109 | 0.399 |
| DLco, % predicted | 0.979 | 0.950–1.010 | 0.180 | 0.947 | 0.902–0.995 | 0.030* | 1.004 | 0.961–1.049 | 0.859 |
| Histology, NSCLC | 0.536 | 0.106–2.715 | 0.451 | 0.188 | 0.027–1.297 | 0.090 | Not calculated | ||
| Stage I vs. II-III | 0.775 | 0.233–2.573 | 0.677 | 0.594 | 0.151–2.342 | 0.457 | Not calculated | ||
| Primary tumor size, mm | 1.024 | 0.990–1.059 | 0.167 | 1.036 | 0.991–1.083 | 0.119 | 0.996 | 0.932–1.063 | 0.896 |
| ILD pattern, UIP | 2.111 | 0.760–5.863 | 0.157 | 3.786 | 0.960–14.933 | 0.057 | 1.212 | 0.251–5.851 | 0.811 |
| Preoperative steroid use, + | 1.251 | 0.257–6.089 | 0.781 | 1.130 | 0.122–10.50 | 0.915 | 1.452 | 0.152–13.87 | 0.746 |
| Preoperative pirfenidone use, + | 1.625 | 0.178–14.80 | 0.667 | Not calculated | Not calculated | ||||
| Surgical procedure, lobectomy | 1.45 | 0.521–4.033 | 0.477 | – | – | – | – | – | – |
| Operative time, min | 1.010 | 1.003–1.018 | 0.008* | 1.017 | 1.005–1.030 | 0.007* | 1.005 | 0.995–1.015 | 0.321 |
| Bleeding volume, mL | 1.002 | 1.001–1.004 | 0.002* | 1.003 | 1.000–1.005 | 0.019* | 1.004 | 0.999–1.009 | 0.131 |
| HMGB1, ng/mL | 1.141 | 1.050–1.239 | 0.002* | 1.170 | 1.054–1.298 | 0.003* | 0.926 | 0.653–1.313 | 0.665 |
| (b) Multivariate analysis including operative time | |||||||||
| VC, % predicted | 0.966 | 0.923–1.011 | 0.132 | 0.983 | 0.906–1.068 | 0.697 | 0.946 | 0.891–1.004 | 0.070 |
| FEV1, % predicted | 0.994 | 0.953–1.038 | 0.795 | 0.977 | 0.908–1.052 | 0.541 | 1.001 | 0.947–1.059 | 0.959 |
| Operative time, min | 1.010 | 1.002–1.018 | 0.010* | 1.017 | 1.003–1.032 | 0.018* | 1.008 | 0.998–1.019 | 0.119 |
| HMGB1, ng/mL | 1.119 | 1.023–1.224 | 0.014* | 1.178 | 1.037–1.338 | 0.012* | 0.792 | 0.534–1.175 | 0.247 |
| (c) Multivariate analysis including bleeding volume | |||||||||
| VC, % predicted | 0.961 | 0.913–1.011 | 0.125 | 0.979 | 0.896–1.070 | 0.640 | 0.932 | 0.867–1.002 | 0.055 |
| FEV1, % predicted | 0.997 | 0.950–1.047 | 0.910 | 0.955 | 0.880–1.036 | 0.269 | 1.025 | 0.956–1.099 | 0.488 |
| Bleeding volume, mL | 1.003 | 1.001–1.005 | 0.009* | 1.003 | 1.001–1.005 | 0.017* | 1.006 | 1.000–1.013 | 0.045* |
| HMGB1, ng/mL | 1.114 | 1.023–1.215 | 0.014* | 1.170 | 1.027–1.332 | 0.019* | 0.785 | 0.524–1.175 | 0.240 |
AE-ILD acute exacerbation of interstitial lung disease; OR Odds ratio; CI confidence interval; DLco diffusing capacity for carbon monoxide; FEV1 forced expiratory volume in one second; FVC forced vital capacity; HMGB1 high-mobility group box 1; ILD interstitial lung disease; NSCLC non-small cell lung cancer; SCLC small cell lung cancer; UIP usual interstitial pneumonia; VC vital capacity.
*P < 0.05 Logistic regression analysis.